Evaluation of the efficacy of SGLT2 inhibitors in reducing recurrence after radiofrequency ablation in patients with type 2 diabetes mellitus combined with atrial fibrillation
Evaluation of the efficacy of SGLT2 inhibitors in reducing recurrence after radiofrequency ablation in patients with type 2 diabetes mellitus combined with atrial fibrillation
Objective The aim of this study was to investigate the long-term efficacy of Sodium-glucose cotransporter 2 inhibitor (SGLT2i) on atrial tachyarrhythmia recurrence after catheter-based radiofrequency ablation (CA) in patients with type 2 diabetes mellitus (T2DM).Methods A total of 151 T2DM patients with atrial fibrillation who received CA in the Cardiovascular Department of the Sixth Hospital of Shanxi Medical University were retrospectively included.Patients were divided into SGLT2i group (n=62) and non-SGLT2I group (n=89) according to whether they received SGLT2i therapy after CA therapy.The baseline demographic characteristics and drug use of patients in the two groups were collected and followed up for 2 years to observe whether the patients in the two groups had recurrent atrial tachyarrhythmia.The relevant factors closely related to the recurrence outcome were screened by univariate Logistic regression,and confounders were adjusted by multivariate Logistic regression.ROC curve was used to evaluate the effect of SGLT2i therapy on recurrence after CA in T2MD patients.Results The study included 151 patients,including 62 patients in the SGLT2i treatment group and 89 patients in the non-SGLT2i treatment group.Patients in the SGLT2 group had a lower body mass index (BMI) than those in the non-SGLT2 group (P=0.029),and there were no statistically significant other differences between the two groups At 2-year follow-up,29 of 151 patients had recurrent atrial tachyarrhythmia,and the recurrence rate of atrial tachyarrhythmia was significantly lower in the SGLT2i group than in the non-SGLT2I group (8.06％ vs.26.97％,P=0.004).After calibrating other relevant factors by multifactorial analysis,SGLT2i treatment showed a protective effect against recurrence of atrial tachyarrhythmias occurring after CA (OR=0.20,95％CI:0.06～0.67,P=0.009),and the AUC of the ROC curve was 0.774 (95％CI:0.679～0.870).Conclusion SGLT2i is an independent risk factor for atrial tachyarrhythmia recurrence after CA in patients with T2DM with atrial fibrillation,and treatment with SGLT2i can effectively reduce the recurrence rate within two years after CA.
维普
万方数据